Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation
- PMID: 6609729
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation
Abstract
A series of monoclonal antibodies that define B cell restricted and associated antigens was utilized in an attempt to characterize tumors of B lineage and to relate these tumors to B cell differentiative stages. Antigens that were previously shown to be B cell restricted on normal B lymphocytes were similarly expressed only on B cell malignancies. In contrast, antigens that were B cell associated were also found on tumors of other lineages. Moreover, on the basis of cell surface phenotypes, tumors of B cell origin were divided into three major subgroups, which corresponded to the level of differentiation of the malignant tumor cell: pre-B cell stage (non-T acute lymphoblastic leukemia and chronic myelocytic leukemia in lymphoid blast crisis); the mid-B cell stage (chronic lymphocytic leukemia, poorly differentiated lymphomas); and secretory B cell stage (large cell lymphomas and plasma cell tumors). A hypothetical model is derived that relates the malignant B cell to its normal cellular counterpart on the basis of cell surface expression of this panel of B cell-restricted and B cell-associated antigens.
Similar articles
-
A unique cell surface antigen identifying lymphoid malignancies of B cell origin.J Clin Invest. 1981 Jan;67(1):134-40. doi: 10.1172/JCI110005. J Clin Invest. 1981. PMID: 6969730 Free PMC article.
-
B-cell malignancies and differentiation antigens defined with monoclonal antibodies.Jpn J Clin Oncol. 1983 Sep;13(3):517-31. Jpn J Clin Oncol. 1983. PMID: 6417375
-
[Diagnosis and classification of hematologic tumors using anti-lymphocyte monoclonal antibodies].Gan To Kagaku Ryoho. 1983 Feb;10(2 Pt 2):551-8. Gan To Kagaku Ryoho. 1983. PMID: 6603817 Japanese.
-
Cell surface markers in leukemia: biological and clinical correlations.Crit Rev Oncol Hematol. 1985;2(3):209-60. doi: 10.1016/s1040-8428(85)80003-2. Crit Rev Oncol Hematol. 1985. PMID: 3013441 Review.
-
Immunologic classification of leukemia and lymphoma.Blood. 1986 Jul;68(1):1-31. Blood. 1986. PMID: 2941082 Review.
Cited by
-
Rituximab.Drugs. 1999 Jul;58(1):79-88; discussion 89-90. doi: 10.2165/00003495-199958010-00009. Drugs. 1999. PMID: 10439931 Review.
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233. Arthritis Rheum. 2010. PMID: 20039413 Free PMC article. Clinical Trial.
-
Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.Int J Mol Sci. 2022 May 19;23(10):5686. doi: 10.3390/ijms23105686. Int J Mol Sci. 2022. PMID: 35628495 Free PMC article. Review.
-
Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma.Drugs. 2011 May 7;71(7):885-95. doi: 10.2165/11206720-000000000-00000. Drugs. 2011. PMID: 21568365 Review.
-
Immunotoxins for the treatment of B-cell lymphomas.Mol Med. 1997 Jul;3(7):420-7. Mol Med. 1997. PMID: 9260154 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials